Radiopharm Theranostics Limited
RAD
Rank in Stocks
#29869
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company,... Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Share Price
$0.00276876
Last synced: 2026-11-10
Market Cap
$6.55M
Change (1 day)
0.00%
Change (1 year)
-82.35%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Radiopharm Theranostics Limited (RAD)
Category
Healthcare
Operating Margin for Radiopharm Theranostics Limited (RAD)
Operating Margin as of November 2026 TTM: -2,545.78%
According to Radiopharm Theranostics Limited's latest financial reports, its current operating margin (TTM) is -2,545.78%. At the end of 2025 the company had an operating margin of -284.87%.
Operating Margin history for Radiopharm Theranostics Limited from 2021 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -2,545.78% | 793.66% |
| 2025 | -284.87% | -98.19% |
| 2024 | -15,777.22% | 14.48% |
| 2023 | -13,781.81% | -93.89% |
| 2022 | -225,527.71% | 0.00% |
| 2021 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.02% |
US
|
|
| -149.01% | -99.94% |
US
|
|
| 25.57% | -100.01% |
AU
|
|
| 31.23% | -100.01% |
BE
|
|
| 29.35% | -100.01% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Radiopharm Theranostics Limited's operating margin
What is Radiopharm Theranostics Limited's operating margin?
Radiopharm Theranostics Limited's operating margin is -2,545.78%, as of Nov 2026.
What was Radiopharm Theranostics Limited's operating margin in 2025?
In 2025, Radiopharm Theranostics Limited's operating margin was -284.87%, compared with -15,777.22% in 2024.
How has Radiopharm Theranostics Limited's operating margin changed since 2021?
From 2021 to 2025, Radiopharm Theranostics Limited's operating margin was highest in 2021 (0.00%) and lowest in 2022 (-225,527.71%).
How does Radiopharm Theranostics Limited's operating margin compare with similar companies?
Radiopharm Theranostics Limited's operating margin (-2,545.78%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.